Wockhardt launches authorized generic of Parkinson’s drug

Kolkata, Apr 24 : Pharmaceutical and biotechnology major Wockhardt has launched an authorized generic version of four strengths (50mg, 75mg, 125mg and 200mg) of the triple-drug combination product containing Levodopa, Carbidopa and Entacapone, which are used in treatment of Parkinsons disease.

The Levodopa + Carbidopa + Entacapone tablet is the generic name for the brand Stalevo, owned by Orion Corporation and marketed in the United States by Novartis.

Wockhardt launched the product on Monday and is entitled to 180-days of exclusivity.

Wockhardt was the first-to-file with paragraph-IV certification on four out of six strengths of this product, said Wockhardt Chairman Dr. Habil Khorakiwala.

Pursuant to a settlement of the litigation between Wockhardt and Orion Corporation, Finland, the holder of the NDA, Wockhardt came to an arrangement to launch an authorized generic version with 180-days of exclusivity. The product involved development of a complex API as well as a triple-drug combination formulation, he said.

Incidence of Parkinsons disease is increasing worldwide. According to IMS Health, the total market for this product in the US is about USD 55 million for the above four strengths and even after the 180-days exclusivity the number of competitors to enter the market is expected to be very limited. (IBNS)

Yearly Horoscope of 2012 for the Zodiac Sign:

Sagittarius Scorpio LibraVirgoLeo Cancer Gemini Taurus Aries Pisces Aquarius Capricon

More from pharmaceutical-news:

See the original post here:
Wockhardt launches authorized generic of Parkinson’s drug